Nielsen BioSciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nielsenbio.com
Candin for the Treatment of Common Warts
Phase 3
Active, not recruiting
- Conditions
- Common Warts (Verruca Vulgaris)
- Interventions
- Drug: Candin, Intradermal SolutionDrug: Placebo
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Nielsen BioSciences, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT05889845
- Locations
- 🇺🇸
Cahaba Dermatology, Birmingham, Alabama, United States
🇺🇸Arkansas Pediatric Clinic, Bryant, Arkansas, United States
🇺🇸Johnson Dermatology, Ft. Smith, Arkansas, United States
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Phase 2
Completed
- Conditions
- Warts
- Interventions
- Biological: CANDINOther: Placebo
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Nielsen BioSciences, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT02393417
- Locations
- 🇺🇸
Silverberg MD Inc., Newport Beach, California, United States
🇺🇸BayState Clinical Trials, Watertown, Massachusetts, United States
🇺🇸California Dermatology and Clinical Research Institute, Encinitas, California, United States
Candin Safety & Efficacy Study for the Treatment of Warts
Phase 2
Completed
- Conditions
- WartsHuman Papilloma Virus
- Interventions
- Biological: Candida albicans Skin Test Antigen
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Nielsen BioSciences, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01757392
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
A Multi-center Study of Spherule-Derived Coccidioidin
Phase 3
Completed
- Conditions
- Coccidioidomycosis
- Interventions
- Biological: Spherule-derived coccidioidin
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Nielsen BioSciences, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT00690092
- Locations
- 🇺🇸
Kern Facility Medical Group, Bakersfield, California, United States
🇺🇸Spokane Allergy and Asthma Center, Spokane, Washington, United States
🇺🇸Health Sciences Center AVAHCS, Univ. of Arizona, Tucson, Arizona, United States
Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Phase 2
Completed
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- Biological: Leishmania tropica Skin Test Antigen (LtSTA)Biological: Leishmania tropica Skin Test Antigen Placebo (Placebo)
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Nielsen BioSciences, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00633009
- Locations
- 🇺🇸
California Research Foundation, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath